Vanguard U.S. Multifactor ETF (BATS: VFMF)

Latest news for Vanguard U.S. Multifactor ETF (BATS:VFMF)

Vanguard U.S. Multifactor ETF

Financial Services

Consumer Cyclical

Technology

Industrials

Energy

Healthcare

Consumer Defensive

Basic Materials

Communication Services

Other

Real Estate

The fund invests primarily in U.S. common stocks with the potential to generate higher returns relative to the broad U.S. equity market by investing in stocks with relatively strong recent performance, strong fundamentals, and low prices relative to fundamentals as determined by the advisor. Under normal circumstances, at least 80% of its assets will be invested in securities issued by U.S. companies.

American International Gr

Wells Fargo & Co.

Mueller Industries Inc

Valero Energy Corp.

Abbvie Inc.

Alphabet Inc Cl C

Aflac Inc.

Mgic Investment Corp

Marathon Petroleum Corp.

Hartford Financial Services Group Inc.

Vanguard US Multifactor ETF

Analyst Color

Long Ideas

News

Broad U.S. Equity ETFs

Analyst Ratings

Trading Ideas

ETFs

VFMF

Don&#39;t Overlook This Multi-Factor ETF

Cantor Fitzgerald analyst Brett Knoblauch maintains Applied Digital (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APLD#NASDAQ">APLD</a>) with a Overweight and lowers the price target from $15 to $14.

Price Target

APLD

Cantor Fitzgerald Maintains Overweight on Applied Digital, Lowers Price Target to $14

Evercore ISI Group analyst James West downgrades Noble Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NE#NYSE">NE</a>) from Outperform to In-Line and lowers the price target from $64 to $41.

Downgrades

Evercore ISI Group Downgrades Noble Corp to In-Line, Lowers Price Target to $41

OS Therapies reiterates clinical and regulatory path in recurrent, fully respected osteosarcoma with lung metastases, an indication with no currently approved treatments.
 &nbsp;

OSTX

OS Therapies Says Phase 2b Clinical Trial Of OST-HER2 Achieves Primary Endpoint With Statistical Significance In Prevention Of Recurrent, Fully Resected, Lung Metastatic Osteosarcoma

Interview

BlackRock CEO Larry Fink Says Don't Believe You'll See BlackRock In The Market Buying Whole Companies

Evercore ISI Group analyst James West downgrades Helmerich &amp; Payne (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HP#NYSE">HP</a>) from Outperform to In-Line and lowers the price target from $48 to $39.

Evercore ISI Group Downgrades Helmerich & Payne to In-Line, Lowers Price Target to $39

WIIM

Bank of New York Mellon shares are trading higher following better-than-expected Q4 financial results.

SPRC

SciSparc Says It Is Granted 180-Day Extension Until July 14, 2025, By Nasdaq To Regain Compliance With Minimum Bid Requirement

GS: 3% &#x7C; <a href="https://www.benzinga.com//node/42999133">Goldman Sachs Q4 Investment Banking Fees Rose 24% YoY, Global Banking &amp; Markets Revenue Rose 33%, Provision For Credit Losses Fell 39%</a>
&nbsp;
VCEL: -12% &#x7C; <a href="https://www.benzinga.com//node/42997435">Vericel shares are trading lower after the company issued preliminary FY24 and Q4 net revenue below estimates.</a>
&nbsp;
COMP: 11% &#x7C; <a href="https://www.benzinga.com//node/42998131">Compass shares are trading higher after the company raised its Q4 and FY24 guidance.</a>

Movers

COMP

VCEL

Market-Moving News for January 15th

AVXL

Anavex Life Sciences Reveals Peer-reviewed Publication Of Oral Blarcamesine Phase IIb/III Data In Journal Of Prevention Of Alzheimer's Disease

Seaport Global analyst Kenneth Zener upgrades KB Home (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KBH#NYSE">KBH</a>) from Sell to Neutral.

Upgrades

Seaport Global Upgrades KB Home to Neutral

Prairie expects Average Daily Production: 7,000 – 8,000 barrels of oil equivalent per day (BOEPD), representing a ~300% increase year-over-year.
Prairie plans to actively pursue additional strategic acquisition opportunities, the completion of which will result in an update to guidance to reflect the enhanced scale and value of the Company.

Guidance

PROP

Prairie Operating Expects 2025 Net Income  Of $69M - $102M, Adjusted EBITDA Of $100M - $140M,

Earnings

Goldman Sachs Total Loans Increased 7% During The Year

QBTS

D-wave Quantum Inks Pact With Carahsoft Partner To Expand Distribution Of Quantum Computing Solutions To The Public Sector

Rosenblatt analyst Blair Abernethy maintains Silvaco Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SVCO#NASDAQ">SVCO</a>) with a Buy and maintains $18 price target.

SVCO

Rosenblatt Maintains Buy on Silvaco Group, Maintains $18 Price Target

ZLAB

Zai Lab Highlights Topline Results For TIVDAK In China Subpopulation Of Global Phase 3 innovaTV 301 Trial In Patients With Recurrent or Metastatic Cervical Cancer

Contracts

STRM

Streamline Health Signs New Contract For Use Of eValuator With Deaconess Health System

Goldman Sachs Q4 Investment Banking Fees Rose 24% YoY, Global Banking & Markets Revenue Rose 33%, Provision For Credit Losses Fell 39%

D. Boral Capital analyst Jesse Sobelson maintains New Horizon Aircraft (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOVR#NASDAQ">HOVR</a>) with a Buy and maintains $2 price target.

HOVR

D. Boral Capital Maintains Buy on New Horizon Aircraft, Maintains $2 Price Target

Needham analyst Chris Pierce reiterates TrueCar (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRUE#NASDAQ">TRUE</a>) with a Buy and maintains $5 price target.

Reiteration

TRUE

Needham Reiterates Buy on TrueCar, Maintains $5 Price Target

D. Boral Capital analyst Jason Kolbert maintains Context Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNTX#NASDAQ">CNTX</a>) with a Buy and maintains $9 price target.

CNTX

D. Boral Capital Maintains Buy on Context Therapeutics, Maintains $9 Price Target

Comments

Vanguard U.S. Multifactor ETF

News

Latest news for Vanguard U.S. Multifactor ETF (BATS:VFMF)

Friday, July 12, 2019

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga